As per the letter attached

30th October, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, G. Block, Bandra Kurla Dalal Street, Complex, Bandra (East), Mumbai 400 001 Mumbai - 400 051 Script Code: 500259 Script Code: LYKALABS Dear Sir/Madam, Sub: Outcome of the Board Meeting – 30th October, 2026 Ref: Intimation under Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the SEBI Listing Regulations) With reference to the above captioned subject and pursuant to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors of the Company in their meeting held today i.e. 30th October, 2026, has inter-alia, considered, approved and taken on record the following: Unaudited Financial Results for the second quarter ended 30th September, 2026 Unaudited Financial Results (Standalone & Consolidated) for the second quarter ended 30th September, 2026 alongwith Limited Review Report thereon is enclosed herewith as Annexure -1. Approval of draft notice of Postal Ballot Approved the draft notice of Postal ballot to seek consent from the Members for following matters: a. Approval for re-appointment of Mr. Neeraj Golas as an Independent Director of the Company for a period of 3 consecutive years Reappointment of Director Approved the re-appointment of Mr. Neeraj Golas as an Independent Director of the Company for a period of 3 consecutive years commencing from 16th January, 2027, subject to approval of the Shareholders through postal ballot. The disclosures as required under Regulation 30 of the SEBI Listing Regulations, concerning the above is enclosed as Annexure -2. The above information will also be available on the website of the Company at www.lykalabs.com. The meeting of the Board of Directors commenced at 03:30 PM and concluded at 05:00 PM. Kindly take the same on your record. Thanking you, Yours faithfully, For Lyka Labs Limited Shailendra Agrawal Company Secretary and Compliance Officer Encl.: as above Ok D. KOTHARY & CO. Chartered Accountants INDIA Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended Review Report to The Board of Directors Lyka Labs Limited 1. We have reviewed the accompanying Statement of unaudited standalone financial results of Lyka Labs Limited (the "Company") for the quarter ended September 30, 2026 and year to date from April 1, 2026 to September 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the 'Listing Regulations'). 2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. For D. Kothai y & Co. Chartered Ac iountants FirmiRegVt Nd.\105335W Q, o * MUMBAI * Mehul :el &0ACC0t) (Partner) Membership No. 132650 UDIN: Place: Mumbai Date: 30th October, 2026 102-Ameya House, Next to Azad Nagar Metro Station, Above Standard Chartered Bank, Andheri (W), Mumbai - 400 058. Tel (B): +91 22 6865 1155/1166/1111 • E-mail: info@dkothary.com • Website : www.dkothary.com Lyka Labs Limited LYK/V Corporate Office : Ground floor, Spencer Building, 30, Forjett Street, Grant Road (West), Mumbai - 400 036 \ • Phone : 6611 2200/290 Website : www.lykalabs.com • Email: enquiry@lykalabs.com HealthcareThroughInnovation Statement of Standalone Unaudited Financial Results for the Quarter and Half Year Ended 30th September, 2026 in lakhs) Quarter Ended Half Year Ended Year Ended Particulars 30th Sept, 2026 30th Jun, 2026 30th Sept, 2025 30th Sept, 2026 30th Sept, 2025 31st Mar, 2026 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) Revenue Revenue from Operations 4419.95 4230.94 3297.03 8650.89 6214.67 12090.53 Other Income 58.96 41.85 132.49 100.81 209.83 397.44 II Total Income 4478.91 4272.79 3429.52 8751.70 6424.51 12487.96 Expenses (a)Cost of Materials Consumed 1357.50 1120.41 896.91 2477.91 1701.85 3177.43 (b)Purchase of Stock in trade 465.36 750.15 325.15 1215.51 550.01 1479.99 (c)Change in inventories of Finished Goods, (33.75) (225.72) 23.50 (259.47) 39.47 (107.94) work-in-progress and stock-in-trade (d)Employee benefits expense 1256.56 1147.61 1032.75 2404.17 1930.99 4160.22 (e)Finance Costs 102.18 100.82 78.58 203.00 163.72 332.67 (0 Depreciation and amortisation expense 205.37 200.96 214.95 406.34 426.13 845.98 (g)Other expenses 1013.93 979.21 1336.72 1993.14 1974.63 3621.71 Total Expenses 4367.15 4073.44 3908.57 8440.60 6786.81 13510.05 IV Profit / (Loss) before Exceptional Items and Taxes (II - III) 111.76 199.35 (479.05) 311.10 (362.31) (1022.09) V Exceptional Items (Net) 2301.44 VI Profit / (Loss) before Tax 111.76 199.35 (479.05) 311.10 (362.31) (3323.53) VII Tax Expenses Current Tax 18.00 49.00 Earlier Year Tax 82.79 Deferred Tax (19-75) (10.68) (134.99) (30.43) (130.32) (177.48) VIII Net Profit / (Loss) after Tax 131.50 210.03 (362.07) 341.53 (280.99) (3228.84) IX Other Comprehensive Income (14.40) (Net of Tax) - Net Credit / (Charge) X Total Comprehensive Income / (Loss) 131.50 210.03 (362.07) 341.53 (280.99) (3243.25) Paid up Equity Share Capital (FV ^ 10/- each) 3615.27 3615.27 3615.27 3615.27 3615.27 3615.27 Other Equity 5084.64 XI Basic and diluted earnings per share 0.36 0.58 (1.01) 0.94 (0.78) (8.93) (Not annualised for the quarters) Regd. Office : 4801 / B & 4802 / A, G.I.D.C. Industrial Estate, Ankleshwar - 393 002. • Phone : 02646 221422 / 220549 • Fax : 02640-250692 CIN L24230GJ1976PLC008738 Lyka Labs Limited Corporate Office : Ground floor, Spencer Building, 30, Forjett Street, Grant Road (West), Mumbai - 400 036 \ • Phone : 6611 2200/290 Website : www.lykalabs.com • Email: [Showing first 8,000 characters — download PDF for full document]